A randomized double blind studyh of Ruxolitinib or placebo in combination with Regorafenib in subjects with relapsed or refractory metastatic colorectal cancer.

Administered By

Duke Cancer Institute

Awarded By

Incyte Corporation

Contributors

Hurwitz, Herbert Ira Principal Investigator

Start/End

October 1, 2014 - September 30, 2019